<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicina (Kaunas)</journal-id><journal-id journal-id-type="iso-abbrev">Medicina (Kaunas)</journal-id><journal-id journal-id-type="pmc-domain-id">3494</journal-id><journal-id journal-id-type="pmc-domain">medicina</journal-id><journal-id journal-id-type="publisher-id">medicina</journal-id><journal-title-group><journal-title>Medicina</journal-title></journal-title-group><issn pub-type="ppub">1010-660X</issn><issn pub-type="epub">1648-9144</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10146833</article-id><article-id pub-id-type="pmcid-ver">PMC10146833.1</article-id><article-id pub-id-type="pmcaid">10146833</article-id><article-id pub-id-type="pmcaiid">10146833</article-id><article-id pub-id-type="pmid">37109712</article-id><article-id pub-id-type="doi">10.3390/medicina59040752</article-id><article-id pub-id-type="publisher-id">medicina-59-00752</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Transient Elastography as the First-Line Assessment of Liver Fibrosis and Its Correlation with Serum Markers</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Uzlova</surname><given-names initials="N">Nikola</given-names></name><xref rid="af1-medicina-59-00752" ref-type="aff">1</xref><xref rid="af2-medicina-59-00752" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mnozil Stridova</surname><given-names initials="K">Katerina</given-names></name><xref rid="af1-medicina-59-00752" ref-type="aff">1</xref><xref rid="af2-medicina-59-00752" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Merta</surname><given-names initials="D">Dusan</given-names></name><xref rid="af3-medicina-59-00752" ref-type="aff">3</xref><xref rid="af4-medicina-59-00752" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4245-5949</contrib-id><name name-style="western"><surname>Rychlik</surname><given-names initials="I">Ivan</given-names></name><xref rid="af1-medicina-59-00752" ref-type="aff">1</xref><xref rid="af2-medicina-59-00752" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1462-5920</contrib-id><name name-style="western"><surname>Frankova</surname><given-names initials="S">Sona</given-names></name><xref rid="af5-medicina-59-00752" ref-type="aff">5</xref><xref rid="c1-medicina-59-00752" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Heo</surname><given-names initials="J">Jeong</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-medicina-59-00752"><label>1</label>Department of Internal Medicine, University Hospital Kr&#225;lovsk&#233; Vinohrady, 100 34 Prague, Czech Republic</aff><aff id="af2-medicina-59-00752"><label>2</label>Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic</aff><aff id="af3-medicina-59-00752"><label>3</label>Anaesthesiology and Resuscitation Department, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic</aff><aff id="af4-medicina-59-00752"><label>4</label>First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic</aff><aff id="af5-medicina-59-00752"><label>5</label>Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic</aff><author-notes><corresp id="c1-medicina-59-00752"><label>*</label>Correspondence: <email>sona.frankova@ikem.cz</email>; Tel.: +420-26-136-2624</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>59</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">434551</issue-id><elocation-id>752</elocation-id><history><date date-type="received"><day>21</day><month>1</month><year>2023</year></date><date date-type="rev-recd"><day>06</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-01 06:25:59.563"><day>01</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medicina-59-00752.pdf"/><abstract><p><italic toggle="yes">Background and objectives</italic>: Recently, rapid progress has been made in the development of noninvasive methods for liver fibrosis assessment. The study aimed to assess the correlation between LSM and serum fibrosis markers to identify patients with advanced liver fibrosis in daily clinical practice. <italic toggle="yes">Methods</italic>: Between 2017 and 2019, 89 patients with chronic liver disease of various etiology, 58 males and 31 females, were enrolled in the study and underwent ultrasound examination, vibration-controlled transient elastography (VCTE), AST to Platelet Ratio Index (APRI score), Fibrosis-4 (FIB-4) score, and enhanced liver fibrosis (ELF) test. <italic toggle="yes">Results</italic>: The diagnoses were as follows: NAFLD (30.3%), HCV (24.3%), HBV (13.1%), ALD (10.1%), other (7.8%). Their median age was 49 (21&#8211;79), and their median BMI was 27.5 (18.4&#8211;39.5). The median liver stiffness measurement (LSM) was 6.7 kPa (2.9&#8211;54.2 kPa), the median of the ELF test was 9.0 (7.3&#8211;12.6), and the median APRI was 0.40 (0.13&#8211;3.13). Advanced fibrosis assessed by LSM was present in 18/89 (20.2%) patients. The LSM values correlated with the ELF test results (r<sup>2</sup> = 0.31, <italic toggle="yes">p</italic> &lt; 0.0001), with the APRI score (r<sup>2</sup> = 0.23, <italic toggle="yes">p</italic> &lt; 0.0001), the age of the patients (r<sup>2</sup> = 0.14, <italic toggle="yes">p</italic> &lt; 0.001), and with the FIB-4 values (r<sup>2</sup> = 0.58, <italic toggle="yes">p</italic> &lt; 0.0001). The ELF test values correlated with the APRI score (r<sup>2</sup> = 0.14, <italic toggle="yes">p</italic> = 0.001), the age (r<sup>2</sup> = 0.38, <italic toggle="yes">p</italic> &lt; 0.0001), and the FIB-4 (r<sup>2</sup> = 0.34, <italic toggle="yes">p</italic> &lt; 0.0001). By determining the confidence intervals of the linear model, we proved that patients younger than 38.1 years have a 95% probability of absence of advanced liver fibrosis when assessed by VCTE. <italic toggle="yes">Conclusions</italic>: We identified APRI and FIB-4 as simple tools for screening liver disease in primary care in an unselected population of patients. The results also showed that individuals younger than 38.1 years had a negligible risk of advanced liver fibrosis.</p></abstract><kwd-group><kwd>vibration-controlled transient elastography</kwd><kwd>ELF test</kwd><kwd>APRI</kwd><kwd>FIB-4</kwd><kwd>liver stiffness</kwd><kwd>advanced fibrosis</kwd></kwd-group><funding-group><award-group><funding-source>Charles University</funding-source><award-id>COOPERATIO 34</award-id><award-id>COOPERATIO 34</award-id></award-group><funding-statement>This study was partially supported by the Charles University research program COOPERATIO 34&#8212;Internal disciplines.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-medicina-59-00752"><title>1. Introduction</title><p>Liver fibrosis is an inevitable consequence of chronic liver diseases and a significant cause of morbidity and mortality in the industrial world [<xref rid="B1-medicina-59-00752" ref-type="bibr">1</xref>]. In 2017, chronic liver disease (CLD) affected a staggering 1.5 billion people worldwide, with the most common causes being non-alcoholic fatty liver disease (NAFLD) (60%), hepatitis B virus (HBV) (29%), hepatitis C virus (HCV) (9%), and alcoholic liver disease (ALD) (2%) [<xref rid="B2-medicina-59-00752" ref-type="bibr">2</xref>]. Despite the high prevalence of CLD, data on the prevalence of cirrhosis in resource-limited settings, particularly in regions outside of Europe, are scarce [<xref rid="B3-medicina-59-00752" ref-type="bibr">3</xref>]. However, in European countries, the median cirrhosis prevalence was 833 cases per 100,000 individuals, with a range of 447 to 1100 cases per 100,000 individuals.</p><p>As obesity rates continue to rise worldwide, the prevalence of NAFLD and its complications are increasing as well. The stage of fibrosis, which refers to the extension of liver scarring, appears to be a significant factor associated with mortality in patients with NAFLD [<xref rid="B4-medicina-59-00752" ref-type="bibr">4</xref>]. Therefore, it is crucial to identify patients who have advanced fibrosis to ensure they receive the necessary medical attention and treatment. Overall, the high prevalence of CLD and its various causes highlight the importance of continuous research and public health efforts to prevent and treat this condition. Identifying patients with advanced fibrosis is just one example of how we can improve patient outcomes and reduce the burden of CLD on individuals and healthcare systems worldwide.</p><p>The degree of liver fibrosis is an important prognostic factor. Early assessment of liver fibrosis plays a crucial role in patients management [<xref rid="B5-medicina-59-00752" ref-type="bibr">5</xref>]. Liver biopsy is an essential tool in diagnosing liver disease and determining the presence of liver fibrosis. However, it requires obtaining a sufficient sample of liver tissue, and its evaluation requires expertise to provide reliable information. Despite providing detailed information, these limitations highlight the need for alternative noninvasive diagnostic methods [<xref rid="B6-medicina-59-00752" ref-type="bibr">6</xref>]. While the liver biopsy is a reliable diagnostic tool, it is also an invasive procedure and carries a risk of serious complications, albeit rare. Due to the associated financial burden and risk, it is desirable to develop noninvasive, easily repeatable, and cost-effective alternatives for assessing the progression of liver fibrosis. This approach would enhance patient safety and comfort, enable serial monitoring of the disease progression, and facilitate the implementation of appropriate treatment strategies. The process of liver fibrogenesis is dynamic, and with time, fibrosis may also regress [<xref rid="B7-medicina-59-00752" ref-type="bibr">7</xref>]. By utilizing noninvasive methods, it becomes possible to monitor the development or the fibrosis regression over time, thereby enabling the determination of the patient&#8217;s prognosis. This approach facilitates the assessment of the disease stage and allows clinicians to adjust management strategies accordingly.</p><p>In the last two decades, rapid progress has been made in the development of noninvasive methods for liver fibrosis assessment. In the past, liver biopsy represented the gold standard for the staging of liver diseases; as an invasive method, it should be used nowadays only to confirm the etiology of liver disease.</p><p>In hepatology, vibration-controlled transient elastography (VCTE) represents the most used and validated method, based on the principle of mechanical energetic impulse. The Fibroscan<sup>&#174;</sup> device (Echosens, Paris, France) works on the principle of VCTE and measures liver stiffness (liver stiffness measurement, LSM). The method was introduced into clinical practice in 2003 and has been validated by many studies across the entire spectrum of liver disease etiologies. After 20 years of use, it is a routine method in daily clinical hepatology practice [<xref rid="B1-medicina-59-00752" ref-type="bibr">1</xref>]. It has become a valid alternative to liver biopsy in staging liver disease, including liver cirrhosis. Yet, despite its reliability, the method has some limitations. The examination of obese patients can be overcome using XL probes with higher penetrance. The results may also be influenced by the patient&#8217;s habitus, the operator&#8217;s experience, a high grade of inflammation, cholestasis, and venous congestion after a meal, or, when the patient suffers from portal vein thrombosis [<xref rid="B8-medicina-59-00752" ref-type="bibr">8</xref>].</p><p>Together with the progress of imaging-based noninvasive methods for liver fibrosis assessment, many specific and non-specific serum markers of fibrogenesis have been investigated. Their use in mathematical models and scores has become an integral component of noninvasive screening tools (noninvasive tests, NITs) in routine clinical practice. Each of these mathematical models correlates with a specific etiology of liver disease: the basic, cheap, and most widely used tests are AST to Platelet Ratio Index (APRI) and the Fibrosis-4 (FIB-4) score. However, the results may fall into the area of uncertainty in 30&#8211;50% of patients [<xref rid="B9-medicina-59-00752" ref-type="bibr">9</xref>]. One of the comprehensive NITs is the enhanced liver fibrosis (ELF) test, which is based on testing markers of acute phase reactants, such as hyaluronic acid (HA), type III procollagen peptide (PIIINP) and tissue inhibitor of metalloproteinase-1 (TIMP1). As validated by a meta-analysis, this test bears a high sensitivity. Still, its specificity is limited to patients with non-alcoholic fatty liver disease (NAFLD/NASH) in determining severe fibrosis [<xref rid="B10-medicina-59-00752" ref-type="bibr">10</xref>].</p><p>Liver cirrhosis or severe fibrosis are considered to be advanced liver disease, i.e., the F3 stage according to the Metavir score, or liver stiffness of more than 10 kPa on transient elastography assessment, or a value of more than 9.8 on the ELF test [<xref rid="B11-medicina-59-00752" ref-type="bibr">11</xref>].</p><p>To date, there has been no study comparing VCTE, the worldwide standard method for investigating the stage of liver fibrosis, with noninvasive laboratory tests commonly used to assess the risk of fibrosis and serum markers of fibrogenesis, in the Czech Republic. This is perhaps due to the fact that VCTE (Fibroscan<sup>&#174;</sup> device) is available only in a few centers in the country. In the clinical practice, hepatologists in the Czech Republic often encounter patients who come to be examined at advanced stages of chronic liver disease or, on the contrary, too early. The lack of a standardized and widely available method for assessing liver fibrosis contributes to this issue.</p><p>The study aimed to assess the correlation between LSM and serum fibrosis markers, in order to identify patients with advanced liver fibrosis in the daily clinical practice at the first contact with patients with chronic liver disease. Conducting a study comparing transient elastography with noninvasive laboratory tests in the Czech Republic would provide valuable insight into the effectiveness of these methods of assessing the risk of fibrosis and serum markers of fibrogenesis. The implementation of a standardized and widely available method of assessing liver fibrosis would allow earlier detection and intervention, ultimately improving patient outcomes, and reducing the burden of chronic liver disease on individuals and healthcare systems in the Czech Republic.</p></sec><sec id="sec2-medicina-59-00752"><title>2. Materials and Methods</title><p>The prospective study was conducted at the outpatient department of the Department of Internal Medicine of the University Hospital Kr&#225;lovsk&#233; Vinohrady, Prague, Czech Republic, between 2017 and 2019. The study was approved by the Ethics Committee and was carried out in compliance with the Helsinki Declaration. All study participants gave written consent to the storage of blood samples and agreed to use blood samples for future research.</p><p>Eighty-nine consecutive patients referred for their first fibrosis assessment by general practitioners, hepatologists, and infectious disease specialists from Prague and Central Bohemia Region were enrolled in the study.</p><p>The study population consisted of individuals with chronic liver disease, as assessed by the referring physician, over the age of 18, who had undergone a valid VCTE examination and had provided their consent to be included in the study. The participants were included consecutively, without prior knowledge of the cause of their liver disease, ensuring that the study population was unselected. The exclusion criteria for the study were: clinical symptoms of acute hepatitis, biliary tree obstruction, heart failure with congestive liver disease, and the inability to perform a VCTE examination; however, none of the participants had to be excluded for these reasons.</p><p>All the patients signed an informed consent to participate in the study before any study procedure. The cohort included patients with alcoholic liver disease (ALD), chronic hepatitis C (HCV), chronic hepatitis B (HBV), HCV/HIV coinfection, non-alcoholic fatty liver disease (NAFLD), primary sclerosing cholangitis (PSC), Wilson&#8217;s disease, or so far undetermined liver disease. All the patients underwent ultrasound examination, and on the same day, they provided their medical history data, underwent VCTE (FibroScan 502 and Compact 530, Echosens, Paris, France), and blood tests for the assessment of the serum fibrosis markers (APRI score, FIB-4 score, and ELF test). The controlled attenuation parameter (CAP) to assess the stage of liver steatosis was evaluated in 48 patients in whom LSM was performed.</p><sec id="sec2dot1-medicina-59-00752"><title>2.1. Vibration-Controlled Transient Elastography</title><p>The LSM was performed using VCTE (Fibroscan<sup>&#174;</sup>, Echosens, Paris, France). One experienced examiner, unaware of the serum fibrosis test results, completed all the examinations [<xref rid="B12-medicina-59-00752" ref-type="bibr">12</xref>] after three hours of the patient&#8217;s fasting [<xref rid="B13-medicina-59-00752" ref-type="bibr">13</xref>]. The M or XL probes were used appropriately according to the body mass index of the examined subject. The LSM value is given in kPa, with a range of 2.5&#8211;75 kPa. The quality of the examination was defined, according to the instruction of the manufacturer, as ten valid measurements with IQR/median &#8804; 30% [<xref rid="B14-medicina-59-00752" ref-type="bibr">14</xref>,<xref rid="B15-medicina-59-00752" ref-type="bibr">15</xref>]. The LSM value of 10 kPa was considered to be the cut-off value for advanced liver fibrosis [<xref rid="B16-medicina-59-00752" ref-type="bibr">16</xref>].</p></sec><sec id="sec2dot2-medicina-59-00752"><title>2.2. Laboratory Assessments</title><p>The following laboratory parameters were assessed after at least three hours of fasting period, on the same day of the transient elastography examination: total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), &#947;-glutamyltransferase (GGT), albumin, and platelet count.</p><p>The pre-analytic and analytic phases of the laboratory samples analysis were conducted in accordance with the standards of the Central Laboratory of the University Hospital Kr&#225;lovsk&#233; Vinohrady (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fnkv.cz/lab/lp_uld/_start.htm">https://www.fnkv.cz/lab/lp_uld/_start.htm</uri>, accessed on 4 July 2022).</p></sec><sec id="sec2dot3-medicina-59-00752"><title>2.3. ELF Test</title><p>ELF test is a noninvasive blood test measuring three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen type III N-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase I (TIMP1). The blood was drawn at the same time as the blood for the other laboratory tests, and the serum was stored at &#8722;80 &#176;C until the analysis was performed. The testing was performed using an ADVIA Centaur XP (Siemens Healthcare Diagnostics Inc., Westchester, NY, USA). The results were calculated using the algorithm provided by the manufacturer, ELF score = 2.278 + 0.851 ln(HA) + 0.751 ln(CPIIINP) + 0.394 ln(CTIMP1) [<xref rid="B17-medicina-59-00752" ref-type="bibr">17</xref>]. The value of the ELF test 10.51 was considered to be the cut-off value for advanced fibrosis.</p></sec><sec id="sec2dot4-medicina-59-00752"><title>2.4. APRI and FIB-4</title><p>APRI and FIB-4 represent the basic biochemical scores.</p><p>APRI was calculated according to the following formula [<xref rid="B18-medicina-59-00752" ref-type="bibr">18</xref>]:<disp-formula id="FD1-medicina-59-00752"><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mtext>&#160;</mml:mtext><mml:mi>AST</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi>IU</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi><mml:mo>/</mml:mo><mml:mrow><mml:mi>AST</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi>ULN</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>platelets</mml:mi><mml:mtext>&#160;</mml:mtext></mml:mrow><mml:mn>10</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mrow><mml:mi mathvariant="normal">L</mml:mi><mml:mtext>&#160;</mml:mtext></mml:mrow></mml:mrow></mml:mfrac><mml:mrow><mml:mo>&#215;</mml:mo><mml:mtext>&#160;</mml:mtext></mml:mrow><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Advanced fibrosis is considered improbable when the values are &lt;0.5 and highly probable when the values reach &gt;1.5 [<xref rid="B1-medicina-59-00752" ref-type="bibr">1</xref>].</p><p>FIB-4 was calculated according to the following formula [<xref rid="B19-medicina-59-00752" ref-type="bibr">19</xref>]:<disp-formula id="FD2-medicina-59-00752"><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mi>age</mml:mi><mml:mtext>&#160;</mml:mtext></mml:mrow><mml:mfenced><mml:mrow><mml:mi>years</mml:mi></mml:mrow></mml:mfenced><mml:mrow><mml:mtext>&#160;</mml:mtext><mml:mo>&#215;</mml:mo><mml:mtext>&#160;</mml:mtext><mml:mi>AST</mml:mi><mml:mtext>&#160;</mml:mtext></mml:mrow><mml:mfenced><mml:mrow><mml:mi>IU</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mrow><mml:mi>platelets</mml:mi><mml:mtext>&#160;</mml:mtext></mml:mrow><mml:mn>10</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mrow><mml:mi mathvariant="normal">L</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mo>&#215;</mml:mo><mml:mtext>&#160;</mml:mtext></mml:mrow><mml:msqrt><mml:mrow><mml:mi>ALT</mml:mi></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Advanced fibrosis is considered improbable when the values are &lt;1.45 and highly probable when the values reach &gt;3.25 [<xref rid="B1-medicina-59-00752" ref-type="bibr">1</xref>].</p></sec><sec id="sec2dot5-medicina-59-00752"><title>2.5. Statistical Analysis</title><p>Quantitative data are presented as medians and ranges, and qualitative data are reported as percentages (%). The Shapiro&#8211;Wilk test was used to evaluate the normal distribution of the data. Medians were compared using the <italic toggle="yes">t</italic>-test, Mann-Whitney test, or Kruskal-Wallis test, as appropriate. Linear regression was applied to assess correlations of the studied values, and the demographic data and the factors predicting the presence of advanced fibrosis were examined using multivariate logistic regression analysis.</p><p>A <italic toggle="yes">p</italic>-value of &lt;0.05 indicated statistical significance for all calculations. The statistical analysis was performed using the GraphPad Prism version 9.4.0 for Mac, GraphPad Software, San Diego, CA, USA, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.graphpad.com">www.graphpad.com</uri>, accessed on 4 July 2022, and R programming language version 4.1.3 (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.r-project.org">www.r-project.org</uri>, accessed on 4 July 2022).</p></sec></sec><sec sec-type="results" id="sec3-medicina-59-00752"><title>3. Results</title><p>Eighty-nine patients, 58 males and 31 females, were enrolled in the study. The baseline demographic data are presented in <xref rid="medicina-59-00752-t001" ref-type="table">Table 1</xref>. The diagnoses were as follows: NAFLD/NASH (30, 33.7%), HCV (24, 27.0%), HBV (13, 14.6%), ALD (10, 11.2%), HCV/HIV (5, 5.6%), PSC (1, 1.1%), Wilson&#8217;s disease (1, 1.1%), and unknown (5, 5.7%). The median age of the patients was 49 years (range 21&#8211;79), with a median body mass index (BMI) of 27.5 (18.4&#8211;39.5).</p><p>The median of the LSM was 6.7 kPa (2.9&#8211;54.2 kPa), the median value of the ELF test was 9.0 (range 7.3&#8211;12.6), and the median APRI was 0.40 (range 0.13&#8211;3.13). Advanced fibrosis assessed by LSM was present in 18/89 (20.2%) patients.</p><sec id="sec3dot1-medicina-59-00752"><title>3.1. LSM and NITs Correlations</title><p>The LSM values correlated with the ELF test results (r<sup>2</sup> = 0.31, <italic toggle="yes">p</italic> &lt; 0.0001); the values were in correlation for both males (r<sup>2</sup> = 0.31) and females (r<sup>2</sup> = 0.36). The LSM values of the whole cohort correlated with the APRI score (r<sup>2</sup> = 0.23, <italic toggle="yes">p</italic> &lt; 0.0001); the values were in correlation for males (r<sup>2</sup> = 0.24, <italic toggle="yes">p</italic> &lt; 0.001), but not for females (r<sup>2</sup> = 0.16, N.S.).</p><p>The LSM correlated with the age of the patients (r<sup>2</sup> = 0.14, <italic toggle="yes">p</italic> &lt; 0.001); the values were in correlation for males (r<sup>2</sup> = 0.12, <italic toggle="yes">p</italic> &lt; 0.01) and for females (r<sup>2</sup> = 0.16, <italic toggle="yes">p</italic> = 0.02).</p><p>The LSM values correlated with the FIB-4 values (r<sup>2</sup> = 0.58, <italic toggle="yes">p</italic> &lt; 0.0001), the values were in correlation for males (r<sup>2</sup> = 0.6, <italic toggle="yes">p</italic> &lt; 0.0001) and for females (r<sup>2</sup> = 0.47, <italic toggle="yes">p</italic> = 0.002) (<xref rid="medicina-59-00752-f001" ref-type="fig">Figure 1</xref>).</p><p>The ELF test values correlated with the APRI score (r<sup>2</sup> = 0.14, <italic toggle="yes">p</italic> = 0.001). The values were in correlation for males (r<sup>2</sup> = 0.12, <italic toggle="yes">p</italic> = 0.01) as well as for females (r<sup>2</sup> = 0.18, <italic toggle="yes">p</italic> = 0.04). The ELF test values correlated with age (r<sup>2</sup> = 0.38, <italic toggle="yes">p</italic> &lt; 0.0001). The values were in correlation for males (r<sup>2</sup> = 0.37, <italic toggle="yes">p</italic> &lt; 0.0001) and for females (r<sup>2</sup> = 0.38, <italic toggle="yes">p</italic> = 0.0001). The ELF test values correlated with the FIB-4 (r<sup>2</sup> = 0.34, <italic toggle="yes">p</italic> &lt; 0.0001); the values were in correlation for males (r<sup>2</sup> = 0.32, <italic toggle="yes">p</italic> &lt; 0.0001) and for females (r<sup>2</sup> = 0.50, <italic toggle="yes">p</italic> = 0.006) (<xref rid="medicina-59-00752-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec3dot2-medicina-59-00752"><title>3.2. LSM and NITs Correlations According to Liver Disease Etiology</title><p>The values of noninvasive serum tests and the results of the LSM did not differ significantly between the groups of patients according to the liver disease etiology (<xref rid="medicina-59-00752-t002" ref-type="table">Table 2</xref>).</p><p>In patients with ALD, the LSM values correlated with the ELF test results (r<sup>2</sup> = 0.66, <italic toggle="yes">p</italic> = 0.04) and the APRI (r<sup>2</sup> = 0.74, <italic toggle="yes">p</italic> = 0.02), but did not correlate with age owing to the small cohort size (10 patients).</p><p>We found a correlation in all analyzed variables in the group of patients with viral hepatitis: LSM and age (r<sup>2</sup> = 0.56, <italic toggle="yes">p</italic> &lt; 0.0001), LSM and ELF (r<sup>2</sup> = 0.60, <italic toggle="yes">p</italic> &lt; 0.0001), LSM and APRI (r<sup>2</sup> = 0.42, <italic toggle="yes">p</italic> = 0.02), and LSM and FIB-4 (r<sup>2</sup> = 0.62, <italic toggle="yes">p</italic> = 0.0003).</p><p>The values correlated in the NAFLD/NASH patients for LSM and age (r<sup>2</sup> = 0.46, <italic toggle="yes">p</italic> = 0.01), LSM and ELF (r<sup>2</sup> = 0.58, <italic toggle="yes">p</italic> = 0.0008), but the correlation was not statistically significant between LSM and APRI, and LSM and FIB-4.</p><p>The group of other diagnoses, consisting of mere seven patients, was not evaluated owing to the small sample size.</p></sec><sec id="sec3dot3-medicina-59-00752"><title>3.3. Factors Predicting Advanced Liver Fibrosis</title><p>By the determination of the confidence intervals of the linear model, we proved that patients younger than 38.1 years have a 95% probability of absence of advanced liver fibrosis (&gt;10 kPa) when liver fibrosis is assessed by VCTE (<xref rid="medicina-59-00752-f003" ref-type="fig">Figure 3</xref>).</p><p>The age cut-offs were also calculated separately for the two largest sub-groups of patients in the study; in the groups of patients with viral hepatitis and NAFLD/NASH, the cut-off points for age predicting the high probability of absence of advanced fibrosis were 39.0 years and 35 years, respectively (<xref rid="app1-medicina-59-00752" ref-type="app">Supplementary Figures S1 and S2</xref>).</p><p>Furthermore, the factors predicting the presence of advanced fibrosis in the entire cohort of patients were analyzed. Only age was the factor predicting the presence of advanced fibrosis at the first hepatologic examination in our cohort of patients (OR 1.05 for one year increment, 95% CI 1.0&#8211;1.1). Neither the female sex (OR 0.83, 95% CI 0.24&#8211;2.63), nor BMI &gt; 30 (0.83, 95% CI 0.58&#8211;6), or diagnosis of NAFLD/NASH (OR 1.37, 95% CI 0.39&#8211;4.63) predicted the presence of advanced liver fibrosis (<xref rid="medicina-59-00752-f004" ref-type="fig">Figure 4</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-medicina-59-00752"><title>4. Discussion</title><p>Our cohort of patients was unselected and referred to their first hepatological examination by primary care physicians, hepatologists, and infectious disease specialists. This population group reflects the distribution of liver disease etiology in the general population in western countries [<xref rid="B20-medicina-59-00752" ref-type="bibr">20</xref>].</p><p>At their first hepatological examination, we identified advanced liver fibrosis in 18/89 (20.2%) patients [<xref rid="B21-medicina-59-00752" ref-type="bibr">21</xref>]. In a French study, screening the stage of liver disease in a general population older than 45 years, advanced fibrosis, or cirrhosis (F3 and F4) were found in 98 (8.2%) subjects out of 1190 subjects screened by VCTE. NAFLD was the most common cause of underlying liver disease (52 patients). The LSM turned out to be a valuable and specific tool to screen cirrhosis in the general population and to detect undiagnosed chronic liver disease in these so far healthy individuals.</p><p>In our cohort, an LSM value lower than 10 kPa was considered to exclude the presence of advanced liver disease according to the Baveno VI Consensus recommendations. However, a multicenter study published in 2021 resulted in the redefinition of the dual cut-offs for the LSM, with values below &lt;8 kPa (or &lt;7 kPa for viral hepatitis) and above 12 kPa showing better diagnostic accuracy in compensated advanced chronic liver disease (cACLD), compared to the previous cut-offs of &lt;10 kPa and &gt;15 kPa recommended by the Baveno VI Consensus [<xref rid="B16-medicina-59-00752" ref-type="bibr">16</xref>]. The findings indicate that a considerable proportion of younger patients could be classified as having advanced liver disease, emphasizing the importance of early diagnosis to prevent disease progression and the development of complications such as liver cirrhosis decompensation and hepatocellular carcinoma. Therefore, prompt detection and management of liver disease in this age group are critical to improve the prognosis and reduce the associated morbidity and mortality.</p><p>In the Czech Republic, VCTE by Fibroscan<sup>&#174;</sup> is not widely available to be used as a screening tool in the general population. It is available only in large volume hepatological centers focused on the treatment of viral hepatitis. Therefore, the noninvasive serum markers could represent a reliable diagnostic alternative in the first-line assessment.</p><p>In our unselected cohort of patients with various liver diseases, the serum markers of fibrosis showed a good correlation with the examination by VCTE. Based on our results, we identified APRI and FIB-4 as simple tools for screening liver disease in primary care, independent of the etiology of liver disease. These tests are based on routinely performed and financially affordable biochemical and blood parameters, routinely available as part of regular medical and preventive examinations. In a small study conducted in 2019, the APRI/FIB-4 combination performed well in predicting significant liver fibrosis, while the FIB-4 alone did well in predicting cirrhosis [<xref rid="B22-medicina-59-00752" ref-type="bibr">22</xref>]. These noninvasive biochemical markers could be used as a screening tool instead of the LSM.</p><p>The individual methods are usually validated for particular etiologies of liver disease based on the data published in previous studies [<xref rid="B5-medicina-59-00752" ref-type="bibr">5</xref>]. However, the study performed by Innes et al. analyzed the performance of routine risk scores to predict long-term cirrhosis complications in the general population. The APRI score exhibited the highest discriminative ability, followed by the FIB-4 score [<xref rid="B23-medicina-59-00752" ref-type="bibr">23</xref>].</p><p>Our results also showed that individuals older than 38.1 years, independent of sex, are at a higher risk of liver disease, especially in the group of patients with NAFLD/NASH and metabolic syndrome.</p><p>This finding is particularly notable, as age is not typically considered a significant risk factor for liver fibrosis. Previous studies have identified a spectrum of risk factors for liver fibrosis, including obesity, presence of diabetes, and regular alcohol consumption. However, the association between age and liver fibrosis is less well-established. Considering the pathophysiological mechanisms of liver fibrosis development, which is determined by, among other factors, the length of time of the presence of liver disease and the amplifying factors [<xref rid="B24-medicina-59-00752" ref-type="bibr">24</xref>], we can conclude that the occurrence of liver disease shifts to younger age.</p><p>In 2020, a UK population-based study was published with the aim of identifying the presence of steatosis and fibrosis in individuals aged from 18 to 35 years using VCTE. The study involved 4021 participants with a mean age of 24 years. One in five young people had steatosis, and one in forty had significant fibrosis around the age of 24 years [<xref rid="B25-medicina-59-00752" ref-type="bibr">25</xref>].</p><p>The aim of a U.S. study was to assess the prevalence of alcohol-associated fatty liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) in a representative U.S. cohort utilizing VCTE to measure hepatic steatosis and suspected fibrosis in adolescents and young adults (age between 15 and 39 years). In the group of 1319 participants, ALD was present in 56.59% of examined individuals. In those with suspected ALD, significant fibrosis (F&#8201;&#8805; F2) was present in 12.3%, and severe fibrosis (F &#8805; F3) was present in 6.31% of the enrolled patients. Similarly, in subjects without excessive alcohol consumption, suspected NAFLD was present in 40.04%. In those with suspected NAFLD, significant fibrosis (F&#8201;&#8805; F2) was present in 31.07%, and suspected advanced fibrosis (F &#8805; F3) was present in 20.15% [<xref rid="B26-medicina-59-00752" ref-type="bibr">26</xref>]. Based on the existing strong evidence that alcohol-related liver disease and NAFLD shift to younger age, we can presume an increasing incidence of advanced liver disease and related complications also in younger individuals. These patients are, therefore, at a higher risk of progression of liver disease and its complications, i.e., HCC [<xref rid="B27-medicina-59-00752" ref-type="bibr">27</xref>,<xref rid="B28-medicina-59-00752" ref-type="bibr">28</xref>].</p><p>The early identification of individuals with advanced liver fibrosis is crucial to assess the patient&#8217;s prognosis and to establish the appropriate therapeutical approach, including enrolment into the HCC surveillance programs. Based on published data, it is feasible to predict the risk of advanced liver disease without the need to adopt costly, proprietary, or invasive methods. The scores can be easily calculated from the data collected for other purposes [<xref rid="B23-medicina-59-00752" ref-type="bibr">23</xref>].</p><p>The best approach is to diagnose chronic liver disease before it becomes symptomatic. In the Czech Republic, the system of compulsory health insurance guarantees preventive medical assessments at regular biennial intervals from the age of 18 years, which can identify individuals at risk of liver disease. Furthermore, this approach could refer these selected patients to a specialized hepatological examination.</p><p>NAFLD/NASH has become the most common cause of liver disease, and according to the meta-analyses published in 2019 and 2022, its prevalence reaches 29.8&#8211;32.4% of the global population. It is continuing to increase at an alarming rate [<xref rid="B20-medicina-59-00752" ref-type="bibr">20</xref>,<xref rid="B29-medicina-59-00752" ref-type="bibr">29</xref>]. One in five individuals with NAFLD present with NASH [<xref rid="B30-medicina-59-00752" ref-type="bibr">30</xref>] with progressive fibrosis representing the risk of chronic liver failure and HCC [<xref rid="B31-medicina-59-00752" ref-type="bibr">31</xref>,<xref rid="B32-medicina-59-00752" ref-type="bibr">32</xref>]. The prevalence is higher in patients with comorbidities, such as type 2 diabetes (55.5%). Also, in our cohort of patients, NAFLD represented the most prevalent etiology of liver disease. Despite being a highly prevalent liver disease that can lead to severe health, economic, and social consequences, NAFLD was found to be receiving far too little attention in national health agendas globally [<xref rid="B33-medicina-59-00752" ref-type="bibr">33</xref>].</p><p>The limitation of our study is the relatively small sample size of the study population and the absence of knowledge of more demographic characteristics of the individual included in the study, such as the presence of diabetes or drinking habits. These factors could also be included in the analysis of predictors of advanced fibrosis. Nevertheless, the study provides important insights into the prevalence of liver fibrosis in the study population in the Czech Republic. Future studies with larger sample sizes may help to validate these pilot findings further.</p></sec><sec sec-type="conclusions" id="sec5-medicina-59-00752"><title>5. Conclusions</title><p>We identified APRI and FIB-4 as simple tools for screening liver disease in primary care in an unselected population of patients, correlating with LSM results. The study provides evidence that there is correlation between LSM and serum fibrosis markers, even in an unselected cohort of patients, independently of the etiology of liver disease. The results also showed that individuals younger than 38.1 years had a negligible risk of advanced liver fibrosis.</p><p>The serum fibrosis markers could serve as a screening tool in an unselected patient population in primary care and help specialists who take care of patients at risk of liver diseases, such as diabetologists, cardiologists, and bariatricians.</p></sec></body><back><ack><title>Acknowledgments</title><p>We express our gratitude to the patients participating in the study and all the nurses for their excellent assistance.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-medicina-59-00752"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/medicina59040752/s1">https://www.mdpi.com/article/10.3390/medicina59040752/s1</uri>. Figure S1: Correlation of LSM and age in patients with viral hepatitis. Figure S2: Correlation of LSM and age in patients with NAFLD/NASH.</p><supplementary-material id="medicina-59-00752-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medicina-59-00752-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, N.U., S.F. and I.R; methodology, N.U., S.F., D.M. and I.R; software, S.F. and D.M.; validation, N.U., S.F. and D.M.; formal analysis, N.U., S.F. and D.M; investigation, N.U., S.F., I.R. and K.M.S.; data curation, N.U. and S.F.; writing&#8212;original draft preparation, N.U., S.F. and D.M; writing&#8212;review and editing, N.U., S.F., D.M., K.M.S. and I.R.; visualization, D.M.; supervision, S.F. and I.R.; project administration, N.U.; funding acquisition, I.R. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was approved by the Ethics Committee &#8220;Eticka Komise Fakultni Nemocnice Kr&#225;lovsk&#233; Vinohrady&#8221; on 1 November 2017, study approval Number EK-VP48/0/2017 (approval date 1 Novemeber 2017), and was carried out in compliance with the Helsinki Declaration.</p></notes><notes><title>Informed Consent Statement</title><p>All study participants gave written consent to the storage of blood samples and agreed to use blood samples for future research. The written consent was obtained before any study procedure.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets used and analyzed in the study are available from the corresponding author by request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-medicina-59-00752"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for Study of Liver</collab><collab>Asociacion Latinoamericana para el Estudio del Higado</collab></person-group><article-title>EASL-ALEH Clinical Practice Guidelines: Noninvasive tests for evaluation of liver disease severity and prognosis</article-title><source>J. Hepatol.</source><year>2015</year><volume>63</volume><fpage>237</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.04.006</pub-id><pub-id pub-id-type="pmid">25911335</pub-id></element-citation></ref><ref id="B2-medicina-59-00752"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2017 Disease and Injury Incidence and Prevalence Collaborators</collab></person-group><article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#8211;2017: A systematic analysis for the Global Burden of Disease Study 2017</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>1789</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32279-7</pub-id><pub-id pub-id-type="pmid">30496104</pub-id><pub-id pub-id-type="pmcid">PMC6227754</pub-id></element-citation></ref><ref id="B3-medicina-59-00752"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pimpin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cortez-Pinto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Negro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Corbould</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lazarus</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Webber</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sheron</surname><given-names>N.</given-names></name><collab>EASL HEPAHEALTH Steering Committee</collab></person-group><article-title>Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies</article-title><source>J. Hepatol.</source><year>2018</year><volume>69</volume><fpage>718</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.05.011</pub-id><pub-id pub-id-type="pmid">29777749</pub-id></element-citation></ref><ref id="B4-medicina-59-00752"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dulai</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prokop</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ekstedt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hagstrom</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nasr</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic review and meta-analysis</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><fpage>1557</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1002/hep.29085</pub-id><pub-id pub-id-type="pmid">28130788</pub-id><pub-id pub-id-type="pmcid">PMC5397356</pub-id></element-citation></ref><ref id="B5-medicina-59-00752"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL Clinical Practice Guidelines on noninvasive tests for evaluation of liver disease severity and prognosis&#8212;2021 update</article-title><source>J. Hepatol.</source><year>2021</year><volume>75</volume><fpage>659</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.05.025</pub-id><pub-id pub-id-type="pmid">34166721</pub-id></element-citation></ref><ref id="B6-medicina-59-00752"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedossa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dargere</surname><given-names>D.</given-names></name><name name-style="western"><surname>Paradis</surname><given-names>V.</given-names></name></person-group><article-title>Sampling variability of liver fibrosis in chronic hepatitis C</article-title><source>Hepatology</source><year>2003</year><volume>38</volume><fpage>1449</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1016/j.hep.2003.09.022</pub-id><pub-id pub-id-type="pmid">14647056</pub-id></element-citation></ref><ref id="B7-medicina-59-00752"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hytiroglou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Theise</surname><given-names>N.D.</given-names></name></person-group><article-title>Regression of human cirrhosis: An update, 18 years after the pioneering article by Wanless et al</article-title><source>Virchows Arch.</source><year>2018</year><volume>473</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s00428-018-2340-2</pub-id><pub-id pub-id-type="pmid">29589101</pub-id></element-citation></ref><ref id="B8-medicina-59-00752"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tapper</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Castera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Afdhal</surname><given-names>N.H.</given-names></name></person-group><article-title>FibroScan (vibration-controlled transient elastography): Where does it stand in the United States practice</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2015</year><volume>13</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2014.04.039</pub-id><pub-id pub-id-type="pmid">24909907</pub-id></element-citation></ref><ref id="B9-medicina-59-00752"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guha</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Roderick</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>W.</given-names></name></person-group><article-title>Performance of serum marker panels for liver fibrosis in chronic hepatitis C</article-title><source>J. Hepatol.</source><year>2006</year><volume>44</volume><fpage>462</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2005.10.019</pub-id><pub-id pub-id-type="pmid">16427156</pub-id></element-citation></ref><ref id="B10-medicina-59-00752"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vali</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boursier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spijker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Loffler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Verheij</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brosnan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>B&#246;cskei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>Q.M.</given-names></name><collab>LITMUS Systematic Review Team</collab><etal/></person-group><article-title>Enhanced liver fibrosis test for the noninvasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis</article-title><source>J. Hepatol.</source><year>2020</year><volume>73</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.03.036</pub-id><pub-id pub-id-type="pmid">32275982</pub-id></element-citation></ref><ref id="B11-medicina-59-00752"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Franchis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baveno</surname><given-names>V.I.F.</given-names></name></person-group><article-title>Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension</article-title><source>J. Hepatol.</source><year>2015</year><volume>63</volume><fpage>743</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.05.022</pub-id><pub-id pub-id-type="pmid">26047908</pub-id></element-citation></ref><ref id="B12-medicina-59-00752"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Chim</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Yiu</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>H.L.-Y.</given-names></name></person-group><article-title>Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population</article-title><source>J. Gastroenterol. Hepatol.</source><year>2011</year><volume>26</volume><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2010.06510.x</pub-id><pub-id pub-id-type="pmid">21261720</pub-id></element-citation></ref><ref id="B13-medicina-59-00752"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mederacke</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wursthorn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rifai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Manns</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Wedemeyer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bahr</surname><given-names>M.J.</given-names></name></person-group><article-title>Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection</article-title><source>Liver Int.</source><year>2009</year><volume>29</volume><fpage>1500</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2009.02100.x</pub-id><pub-id pub-id-type="pmid">19732330</pub-id></element-citation></ref><ref id="B14-medicina-59-00752"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Forns</surname><given-names>X.</given-names></name><name name-style="western"><surname>Alberti</surname><given-names>A.</given-names></name></person-group><article-title>Noninvasive evaluation of liver fibrosis using transient elastography</article-title><source>J. Hepatol.</source><year>2008</year><volume>48</volume><fpage>835</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2008.02.008</pub-id><pub-id pub-id-type="pmid">18334275</pub-id></element-citation></ref><ref id="B15-medicina-59-00752"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boursier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zarski</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>de Ledinghen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rousselet</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Sturm</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lebail</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fouchard-Hubert</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gallois</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oberti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bertrais</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Determination of reliability criteria for liver stiffness evaluation by transient elastography</article-title><source>Hepatology</source><year>2013</year><volume>57</volume><fpage>1182</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1002/hep.25993</pub-id><pub-id pub-id-type="pmid">22899556</pub-id></element-citation></ref><ref id="B16-medicina-59-00752"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papatheodoridi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hiriart</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Lupsor-Platon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bronte</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boursier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elshaarawy</surname><given-names>O.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>M.</given-names></name><name name-style="western"><surname>Markakis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Payance</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease</article-title><source>J. Hepatol.</source><year>2021</year><volume>74</volume><fpage>1109</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.11.050</pub-id><pub-id pub-id-type="pmid">33307138</pub-id></element-citation></ref><ref id="B17-medicina-59-00752"><label>17.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Siemens Healthcare</collab></person-group><article-title>ELF Physician Brochure</article-title><year>2016</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://marketing.webassets.siemens-healthineers.com/1800000003470658/6d7021e5e01d/elf_physician_brochure_a91dx-160435-xc1-4a00_final-03470658_1800000003470658.pdf" ext-link-type="uri">https://marketing.webassets.siemens-healthineers.com/1800000003470658/6d7021e5e01d/elf_physician_brochure_a91dx-160435-xc1-4a00_final-03470658_1800000003470658.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-11-20">(accessed on 20 November 2022)</date-in-citation></element-citation></ref><ref id="B18-medicina-59-00752"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wai</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Greenson</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Kalbfleisch</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Marrero</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Conjeevaram</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Lok</surname><given-names>A.S.-F.</given-names></name></person-group><article-title>A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C</article-title><source>Hepatology</source><year>2003</year><volume>38</volume><fpage>518</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1053/jhep.2003.50346</pub-id><pub-id pub-id-type="pmid">12883497</pub-id></element-citation></ref><ref id="B19-medicina-59-00752"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterling</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Lissen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clumeck</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Correa</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sulkowski</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Torriani</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Dieterich</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection</article-title><source>Hepatology</source><year>2006</year><volume>43</volume><fpage>1317</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1002/hep.21178</pub-id><pub-id pub-id-type="pmid">16729309</pub-id></element-citation></ref><ref id="B20-medicina-59-00752"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riazi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Azhari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Charette</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Underwood</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>King</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Afshar</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Swain</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>E Congly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>A.-A.</given-names></name></person-group><article-title>The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2022</year><volume>7</volume><fpage>851</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(22)00165-0</pub-id><pub-id pub-id-type="pmid">35798021</pub-id></element-citation></ref><ref id="B21-medicina-59-00752"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roulot</surname><given-names>D.</given-names></name><name name-style="western"><surname>Costes</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Buyck</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Warzocha</surname><given-names>U.</given-names></name><name name-style="western"><surname>Gambier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Czernichow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Le Clesiau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Beaugrand</surname><given-names>M.</given-names></name></person-group><article-title>Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years</article-title><source>Gut</source><year>2011</year><volume>60</volume><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1136/gut.2010.221382</pub-id><pub-id pub-id-type="pmid">21068129</pub-id></element-citation></ref><ref id="B22-medicina-59-00752"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadopoulos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vasileiadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Papavdi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sveroni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Antonakaki</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dellaporta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koutli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Michalea</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manolakopoulos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koskinas</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography</article-title><source>Ann. Gastroenterol.</source><year>2019</year><volume>32</volume><fpage>498</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.20524/aog.2019.0406</pub-id><pub-id pub-id-type="pmid">31474797</pub-id><pub-id pub-id-type="pmcid">PMC6686098</pub-id></element-citation></ref><ref id="B23-medicina-59-00752"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Innes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morling</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Buch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamill</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stickel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guha</surname><given-names>I.N.</given-names></name></person-group><article-title>Performance of routine risk scores for predicting cirrhosis-related morbidity in the community</article-title><source>J. Hepatol.</source><year>2022</year><volume>77</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2022.02.022</pub-id><pub-id pub-id-type="pmid">35271950</pub-id></element-citation></ref><ref id="B24-medicina-59-00752"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pinzani</surname><given-names>M.</given-names></name></person-group><article-title>Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues</article-title><source>Mol. Asp. Med.</source><year>2019</year><volume>65</volume><fpage>37</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2018.09.002</pub-id><pub-id pub-id-type="pmid">30213667</pub-id></element-citation></ref><ref id="B25-medicina-59-00752"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abeysekera</surname><given-names>K.W.M.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Hammerton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Portal</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Heron</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>M.</given-names></name></person-group><article-title>Prevalence of steatosis and fibrosis in young adults in the UK: A population-based study</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2020</year><volume>5</volume><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(19)30419-4</pub-id><pub-id pub-id-type="pmid">31954687</pub-id><pub-id pub-id-type="pmcid">PMC7026693</pub-id></element-citation></ref><ref id="B26-medicina-59-00752"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkhouri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Almomani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le</surname><given-names>P.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Asaad</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sakkal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Noureddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name></person-group><article-title>The prevalence of alcoholic and non-alcoholic fatty liver disease in adolescents and young adults in the United States: Analysis of the NHANES database</article-title><source>BMC Gastroenterol.</source><year>2022</year><volume>22</volume><elocation-id>366</elocation-id><pub-id pub-id-type="doi">10.1186/s12876-022-02430-7</pub-id><pub-id pub-id-type="pmid">35907827</pub-id><pub-id pub-id-type="pmcid">PMC9338651</pub-id></element-citation></ref><ref id="B27-medicina-59-00752"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeo</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kam</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.H.</given-names></name></person-group><article-title>Surveillance of patients with cirrhosis remains suboptimal in the United States</article-title><source>J. Hepatol.</source><year>2021</year><volume>75</volume><fpage>856</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.04.042</pub-id><pub-id pub-id-type="pmid">33965477</pub-id></element-citation></ref><ref id="B28-medicina-59-00752"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singal</surname><given-names>A.G.</given-names></name></person-group><article-title>Surveillance and Diagnosis of Hepatocellular Carcinoma</article-title><source>Clin. Liver Dis.</source><year>2019</year><volume>13</volume><fpage>2</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1002/cld.761</pub-id><pub-id pub-id-type="pmcid">PMC6430214</pub-id><pub-id pub-id-type="pmid">30911378</pub-id></element-citation></ref><ref id="B29-medicina-59-00752"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2021</year><volume>20</volume><fpage>2809</fpage><lpage>2817.e28</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2021.12.002</pub-id><pub-id pub-id-type="pmid">34890795</pub-id></element-citation></ref><ref id="B30-medicina-59-00752"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Razavi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Loomba</surname><given-names>R.</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>A.J.</given-names></name></person-group><article-title>Modeling the epidemic of non-alcoholic fatty liver disease demonstrates an exponential increase in burden of disease</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1002/hep.29466</pub-id><pub-id pub-id-type="pmid">28802062</pub-id><pub-id pub-id-type="pmcid">PMC5767767</pub-id></element-citation></ref><ref id="B31-medicina-59-00752"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanwal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mapakshi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chayanupatkul</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Desiderio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thrift</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Asch</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><fpage>1828</fpage><lpage>1837 e2</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.08.024</pub-id><pub-id pub-id-type="pmid">30144434</pub-id><pub-id pub-id-type="pmcid">PMC6279617</pub-id></element-citation></ref><ref id="B32-medicina-59-00752"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araujo</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Rosso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bedogni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tiribelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bellentani</surname><given-names>S.</given-names></name></person-group><article-title>Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future</article-title><source>Liver Int.</source><year>2018</year><volume>38</volume><issue>(Suppl. S1)</issue><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/liv.13643</pub-id><pub-id pub-id-type="pmid">29427488</pub-id></element-citation></ref><ref id="B33-medicina-59-00752"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarus</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Mark</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Villota-Rivas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palayew</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carrieri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ekstedt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esmat</surname><given-names>G.</given-names></name><name name-style="western"><surname>George</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marchesini</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?</article-title><source>J. Hepatol.</source><year>2022</year><volume>76</volume><fpage>771</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.10.025</pub-id><pub-id pub-id-type="pmid">34895743</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="medicina-59-00752-f001" orientation="portrait"><label>Figure 1</label><caption><p>Correlation of LSM with ELF test (<bold>A</bold>), APRI (<bold>B</bold>), age (<bold>C</bold>) and FIB-4 (<bold>D</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-59-00752-g001.jpg"/></fig><fig position="float" id="medicina-59-00752-f002" orientation="portrait"><label>Figure 2</label><caption><p>Correlation of ELF test with APRI (<bold>A</bold>), age (<bold>B</bold>) and FIB-4 (<bold>C</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-59-00752-g002.jpg"/></fig><fig position="float" id="medicina-59-00752-f003" orientation="portrait"><label>Figure 3</label><caption><p>Correlation of LSM and age. Advanced liver fibrosis is unlikely in individuals younger than 38.1 years. The blue line represents the linear regression model of the correlation between LSM and age. The black points represent the individual patients. The red point represents the cut-off value with the 95% certainty that individuals younger than 38.1 years do not have LSM &gt; 10 kPa. The confidence intervals are in grey. LSM, liver stiffness measurement.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-59-00752-g003.jpg"/></fig><fig position="float" id="medicina-59-00752-f004" orientation="portrait"><label>Figure 4</label><caption><p>Predictors of advanced fibrosis at the first examination. CI, confidence interval. The significant predictor is depicted in red.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-59-00752-g004.jpg"/></fig><table-wrap position="float" id="medicina-59-00752-t001" orientation="portrait"><object-id pub-id-type="pii">medicina-59-00752-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics of the cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Females (<italic toggle="yes">n</italic> = 31)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Males (<italic toggle="yes">n</italic> = 58)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All (<italic toggle="yes">n</italic> = 89)</th></tr></thead><tbody><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Age, years (median, range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54 (23&#8211;69)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47 (2179)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 (21&#8211;79)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Weight, kg (median, range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.2 (4&#8211;125)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.5 (58&#8211;138)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84 (49&#8211;138)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Height, cm (median, range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">165 (150&#8211;178)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">178 (160&#8211;197)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">173 (150&#8211;197)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">BMI, kg/m<sup>2</sup> (median, range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.8 (18.4&#8211;39.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.7 (20.5&#8211;39)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.6 (18.4&#8211;39.5)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Waist circumference, cm (median, range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87 (66&#8211;123)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99 (78&#8211;144)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.5 (66&#8211;144)</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Liver disease etiology</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;NAFLD/NASH</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (35.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (32.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">30 (33.7%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Viral hepatitis (HBV, HCV, HCV/HIV)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (51.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (44.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (47.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;ALD</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (6.45%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (13.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (11.2%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;&#8195;Other and unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (6.45%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (8.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (7.9%)</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Laboratory Data</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">ALT, IU/L, median, range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.5 (16.3&#8211;161.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.2 (12.7&#8211;516.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.9 (12.6&#8211;516.9)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">AST, IU/L, median, range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.7 (16.3&#8211;87.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.9 (15.7&#8211;236.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.8 (15.7&#8211;236.1)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">GGT, IU/L, median, range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.3 (16.2&#8211;160.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.0 (12.6&#8211;514.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.8 (12.6&#8211;514.7)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">ALP, IU/L, median, range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.4 (32.4&#8211;159.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.0 (39.0&#8211;330.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.9 (32.4&#8211;330.6)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Total bilirubin, mg/dL, median, range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45 (0.2&#8211;1.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39 (0.3&#8211;1.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.51 (0.2&#8211;1.8)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Platelets [&#215;10<sup>9</sup>/L], median, range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">224 (122&#8211;398)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">218 (66&#8211;483)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">224 (66&#8211;483)</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Noninvasive Serum Tests</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APRI score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.35 (0.15&#8211;1.08)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48 (0.13&#8211;3.13)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40 (0.13&#8211;3.13)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIB-4 score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1 (0.28&#8211;3.54)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.12 (0.21&#8211;10.75)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 (0.21&#8211;10.75)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ELF score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (7.4&#8211;12.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.95 (7.3&#8211;12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (7.3&#8211;12.6)</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">VCTE Assessment (Fibroscan<sup>&#174;</sup>)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">LSM [kPa]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.9 (3.3&#8211;8.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5 (2.9&#8211;48)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.7 (2.9&#8211;54.2)</td></tr></tbody></table><table-wrap-foot><fn><p>ALD, alcoholic liver disease; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; APRI, AST to Platelet Ratio Index; BMI, body mass index; GGT, gamma-glutamyl transpeptidase; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; HCV/HIV, hepatitis C and human immunodeficiency virus coinfection); LSM, liver stiffness measurement; NAFLD/NASH, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis; VCTE, vibration-controlled transient elastography. The reference upper limits of normal for liver function tests are as follows: ALT 44 IU/L; ALP 132 IU/L; AST, 38 IU/L; GGT, 106 IU/L; total bilirubin 1.2 mg/dL.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="medicina-59-00752-t002" orientation="portrait"><object-id pub-id-type="pii">medicina-59-00752-t002_Table 2</object-id><label>Table 2</label><caption><p>Baseline characteristics of the cohort according to liver disease etiology.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Viral Hepatitis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NAFLD/<break/>NASH</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ALD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Other</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age, years (median, range)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 (21&#8211;79)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 (21&#8211;75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.5 (45&#8211;63)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 (32&#8211;61) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weight, kg (median, range)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79.3 (49&#8211;118)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88 (72&#8211;125)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.5 (61&#8211;138)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87 (77&#8211;102)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Height, cm (median, range)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">172 (156&#8211;192)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">176 (150&#8211;197)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">178 (170&#8211;186)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">172 (165&#8211;193)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> (median, range)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.0 (18.7&#8211;39)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.0 (21&#8211;39)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.4 (18.4&#8211;39.0)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.9 (23.8&#8211;30.1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Waist circumference,</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 (66&#8211;126)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102 (90&#8211;123)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95 (85&#8211;144)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91 (90&#8211;103)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cm (median, range)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td colspan="5" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Laboratory data</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALT, IU/L, median, range</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (19&#8211;356)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 (18&#8211;516)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (18&#8211;42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52 (12&#8211;81)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AST, IU/L, median, range</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 (16&#8211;236)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 (15&#8211;130)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 (20&#8211;75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46 (23&#8211;53)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGT, IU/L, median, range</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51 (9&#8211;1130)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 (17&#8211;404)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 (24&#8211;519)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77 (19&#8211;107)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALP, IU/L, median, range</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71 (32&#8211;169)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77 (44&#8211;212)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75 (60&#8211;124)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 (60&#8211;331)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total bilirubin, mg/dl, median, range</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.50 (0.18&#8211;1.9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58 (0.18&#8211;1.35)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.50 (0.35&#8211;1.69)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.52 (0.35&#8211;0.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Platelets [&#215;10<sup>9</sup>/L], median, range</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">216 (11&#8211;373)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">257 (223&#8211;267)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300 (66&#8211;483)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">234 (159&#8211;431)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td colspan="5" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Noninvasive serum tests</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APRI score</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37 (0.13&#8211;2.49)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55 (0.15&#8211;1.44)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24 (0.19&#8211;3.13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.42 (0.22&#8211;0.79)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIB-4 score</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.04 (0.2&#8211;5.9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.10 (0.34&#8211;2.75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.13 (0.66&#8211;10.75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 (0.42&#8211;2.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ELF score</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (7.4&#8211;11.7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.7 (7.3&#8211;10.5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.4 (9.0&#8211;11.5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.9 (7.8&#8211;12.6)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr><tr><td colspan="5" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">VCTE assessment (Fibroscan<sup>&#174;</sup>)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LSM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.7 (4.2&#8211;42.2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.5 (3.1&#8211;54.2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.5 (3&#8211;44.7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.3 (6.1&#8211;11.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S.</td></tr></tbody></table><table-wrap-foot><fn><p>ALD, alcoholic liver disease; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; APRI, AST to Platelet Ratio Index; BMI, body mass index; GGT, gamma-glutamyl transpeptidase; LSM, liver stiffness measurement; NAFLD/NASH, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis; VCTE, vibration-controlled transient elastography. The reference upper limits of normal for liver function tests are as follows: ALT 44 IU/L; ALP 132 IU/L; AST, 38 IU/L; GGT, 106 IU/L; total bilirubin 1.2 mg/dL.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>